Moderna trial
Moderna is conducting a clinical trial, called the mRNA-1273-P305 clinical trial, on investigational booster vaccines that may protect against the COVID-19 Omicron variant and other variants, and you may be eligible to take part.
mRNA-1273-P305 clinical trial
Moderna is conducting a clinical trial, called the mRNA-1273-P305 clinical trial, on investigational booster vaccines that may protect against the COVID-19 Omicron variant and other variants, and you may be eligible to take part.
The mRNA-1273-P305 clinical trial is evaluating the safety and immune response of investigational Omicron variant vaccines compared to a booster dose of Moderna’s COVID-19 vaccine, SPIKEVAX. This trial is enrolling volunteers 16 years of age or older, who are in good or stable health and have received two or three doses of the COVID-19 vaccine at least 90 days ago.
Participation in this trial lasts up to 13 months, and includes phone calls and approximately 5–7 scheduled visits to the trial site.
Participants will receive a single dose of either one of the investigational Omicron variant vaccines: mRNA-1273.529, mRNA-1273.214, or the already authorized vaccine, SPIKEVAX.
Interested individuals are invited to contact the Chelwest Research Facility on 07827954062.
The study is available on our Chelsea site, but participants willing to travel are very welcome.